Abstract Library

#4587 Exploring the splicing landscape to identify survival-related biomarkers in small intestine neuroendocrine neoplasms

Introduction: The study of small intestine neuroendocrine neoplasms (siNENs) is challenging due to their rarity and complexity. While transcriptomic subtypes have been identified, the mechanisms behind their progression are still unclear. The process of RNA splicing is often altered in cancer, and our group has described that such dysregulation is also present in various NENs.

Conference:

Presenting Author: Ibáñez Costa A

Authors: Ibáñez-Costa A, García Vioque V, Pedraza-Arévalo S, Hernando Cubero J, García A,

Keywords: small intestine neuroendocrine tumour, splicing, biomarker, survival, ki-67, RNA,

#4539 Single-nucleus profiling of the tumour microenvironment in SI-NET patients

Introduction: Small intestinal neuroendocrine tumours (SI-NETs) are frequently present as multiple synchronous primary tumours in the small bowel. They are thought to arise from enterochromaffin (EC) cells in the gut, which account for less than 1% of the intestinal epithelium. Previously reported lack of shared somatic driver alterations in SI-NETs suggests that other, non-genetic mechanisms are likely involved in their tumorigenesis.

Conference:

Presenting Author: Mäkinen N

Authors: Mäkinen N, Kasai Y, Kim G, Thirlwell C, Nakakura E,

Keywords: small intestinal NET, tumour microenvironment, single-nucleus sequencing,

#4466 Molecular characterisation of extrapulmonary mixed adeno-neuroendocrine neoplasms (MiNENs): The NIRVANA sub study

Introduction: Extrapulmonary (EP) mixed neuroendocrine/non-neuroendocrine neoplasms (MiNENs) are rare cancers with a dismal prognosis. The gene mutation profiles are incompletely understood.

Conference:

Presenting Author: Spada F

Authors: Spada F, Pisa E, Ranghiero A, Frassoni S, Bagnardi V,

Keywords: MiNEN, NGS, ESCAT, chemotherapy,

#4291 Novel genomic score predicts survival with immune checkpoint blockade in neuroendocrine neoplasms

Introduction: Immune checkpoint inhibition (ICI) has activity in Grade 3 (G3) neuroendocrine neoplasms (NENs) but predictive biomarkers of overall survival (OS) are currently lacking.

Conference:

Presenting Author:

Authors: Brar T, Sukrithan V, Le D, Xu M, Olowookere C,

Keywords: Neuroendocrine Neoplasm, Immunotherapy, Ipilimumab, Nivolumab, Immune checkpoint inhibitor, biomarker, genomic score,

#4285 Predictive biomarkers for immunotherapy efficacy in neuroendocrine neoplasms

Introduction: The application of immunotherapy in NENs is still in its early stages. Identifying reliable predictive biomarkers of efficacy is critical for research, enabling better selection of patients who are more likely to respond to immunotherapy and improving treatment success rates.

Conference:

Presenting Author: Liang Y

Authors: Liang Y, Sun Z, Jia X, Chen J,

Keywords: immunotherapy, biomarker, neuroendocrine neoplasm,